4-氯-5-甲氧基-3-喹啉甲腈 | 331662-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-5-甲氧基-3-喹啉甲腈
• 英文名称: 4-chloro-5-methoxy-3-quinolinecarbonitrile
• 英文别名: 4-Chloro-5-methoxyquinoline-3-carbonitrile
• CAS: 331662-72-7
• 化学式: C₁₁H₇ClN₂O
• 分子量: 218.642
• InChiKey: UJGRRVNELFZUBY-UHFFFAOYSA-N

物化性质

• 熔点：
  174-176 °C
• 沸点：
  385.3±37.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯苯胺 、 4-氯-5-甲氧基-3-喹啉甲腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以63%的产率得到3-Quinolinecarbonitrile deriv. 2c
  参考文献：
  名称：

  Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles

  摘要：

  Screening of a directed compound library in a yeast-based assay identified 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile (2a) as a Src inhibitor. An enzymatic assay established that 2a was an ATP-competitive inhibitor of the kinase activity of Src. We present here SAR data for 2a which shows that the aniline group at C-4, the carbonitrile group at C-3, and the alkoxy groups at C-6 and C-7 of the quinoline are crucial for optimal activity. Increasing the size of the C-2 substituent of the aniline at C-4 of 2a from chloro to bromo to iodo resulted in a corresponding increase in Src inhibition. Furthermore, replacement of the 7-methoxy group of 2a with various 3-heteroalkylaminopropoxy groups provided increased inhibition of both Src enzymatic and cellular activity. Compound 25, which contains a 3-morpholinopropoxy group, had an IC50 of 3.8 nM in the Src enzymatic assay and an IC50 of 940 nM for the inhibition of Src-dependent cell proliferation.

  DOI：

  10.1021/jm000420z
• 作为产物：
  描述：

  2-氨基-6-甲氧基苯甲酸甲酯 在 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 生成 4-氯-5-甲氧基-3-喹啉甲腈
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of 3-Cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) Inhibitors

  摘要：

  A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50's against MAP kinase kinase, and have potent inhibitory activity in tumor cells. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00580-1

文献信息

• HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS
  申请人：Marsais Francis

  公开号：US20090062279A1

  公开（公告）日：2009-03-05

  The invention is related to compound which comprises at least one radical C═Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C═Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.

  本发明涉及一种化合物，其包含至少一个基团C═Y，其中Y为O或S，以及一个可氧化且不可质子化的氮原子N，其中在氧化时，基团C═Y的至少一个碳原子与氮原子之间的距离(d)在0.3至0.8纳米之间。本发明涉及由公式G定义的新杂环化合物及其制备方法，涉及包含它们的制药组合物以及它们在治疗神经退行性或阿尔茨海默病方面的用途。
• New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
  申请人：Institut National des Sciences Appliquees de Rouen (INSA)

  公开号：EP1731507A1

  公开（公告）日：2006-12-13

  The invention is related to compound which comprises at least one radical C=Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C=Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.

  本发明涉及由至少一个基团C=Y（Y为O或S）和一个可氧化且不可质子化的氮原子N组成的化合物，其中基团C=Y的至少一个碳原子与氮原子之间的距离（d）在氧化时介于0.3至0.8纳米之间。 本发明涉及由式 G 定义的新杂环化合物、 它们的制备、包含它们的药物组合物以及它们作为治疗剂的用途，特别是在治疗神经退行性疾病或阿尔茨海默病中的用途。
• NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS
  申请人：Insa Rouen

  公开号：EP1868998A2

  公开（公告）日：2007-12-26
• US7977354B2
  申请人：——

  公开号：US7977354B2

  公开（公告）日：2011-07-12
• [EN] NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, PREPARATION ET UTILISATION EN TANT QUE MEDICAMENTS, NOTAMMENT EN TANT QU'AGENTS ANTI-ALZHEIMER
  申请人：INSA ROUEN

  公开号：WO2006103120A2

  公开（公告）日：2006-10-05

  [EN] The invention is related to compound which comprises at least one radical C=Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C=Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.
  [FR] L'invention concerne des composés contenant au moins un radical C=Y, Y étant O ou S, et un atome d'azote N oxydable ou non protonable, la distance (d) entre le ou les atomes de carbone du groupe radical C=Y et l'atome d'azote, si oxydé, étant comprise entre 0,3 et 0,8 nm. L'invention concerne également de nouveaux composés hétérocycliques représentés par la formule G, leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en tant qu'agents thérapeutiques, notamment dans le traitement de maladies neurodégénératives ou de la maladie d'Alzheimer.